ABBV-CLS-484 (C007B-324892)

ABBV-CLS-484 is a potent PTPN1 and PTPN2 inhibitor with subnanomolar activity. ABBV-CLS-484 has antitumor activity, enhances the immune response and increases the sensitivity of tumors to immune-mediated killing.In VitroABBV-CLS-484 acts on both tumor cells and the host immune system, inducing unique transcriptional changes in the myeloid and lymphocyte populations of the tumor microenvironment, enhancing CD 8+ T cell activation and effector functions while reducing the expression of genes classically associated with T cell depletion and dysfunction. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoABBV-CLS-484 promotes anti-tumor immunity as a monotherapy and, when combined with anti-PD-1, leads to significant tumor regression, even in models resistant to anti-PD-1 treatment, such as 4T1 and EMT6. MCE has not independently confirmed the accuracy of these methods. They are for reference only.Form:Solid.

Specifications and Purity: ≥99%

Molecular Formula: C17H24FN3O4S

Molecular Weight: 385.45

PubChem CID: 155103607

Isomeric SMILES: CC(C)CCN[C@@H]1CCC2=CC(=C(C(=C2C1)F)N3CC(=O)NS3(=O)=O)O